Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.
Carisma Therapeutics has raised $30.0M in total funding. The most recent round was Series C. The last funding was announced in September 2022.
Carisma Therapeutics's investors include AbbVie, HealthCap, IP Group, 4BIO Capital, Blood Cancer United, Inc..
Carisma Therapeutics is headquartered in Philadelphia, United States.
Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.
Carisma Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Carisma Therapeutics — Funding & Investors." VCBacked, September 21, 2022, https://www.vcbacked.co/company/carisma-therapeutics. Accessed November 11, 2026.
VCBacked. (2022). Carisma Therapeutics — Funding & Investors. Retrieved November 11, 2026, from https://www.vcbacked.co/company/carisma-therapeutics
{{cite web |title=Carisma Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/carisma-therapeutics |website=VCBacked |access-date=November 11, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Carisma Therapeutics? Request a listing update